How Mazur was paid
$3.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Total |
|---|---|---|---|---|
| Leonard MazurChief Executive Officer and Executive Chairman | $166,250 | $2,975,000 | $647,723 | $3,788,973 |
| Myron HolubiakExecutive Vice Chairman | $450,000 | $1,487,500 | $242,896 | $2,180,396 |
| Myron CzuczmanChief Medical Officer | $225,000 | $1,443,750 | $323,862 | $1,992,612 |
What changed and why
- $3.8M$3,788,973 was CEO total compensation in 2025, including $2,975,000 in stock awards and $647,723 in option awards.
- $166K$166,250, $450,000, and $225,000 were the three named executives’ unchanged 2025 salaries.
- The Company did not reprice or otherwise modify executive officers’ outstanding options during fiscal 2025.
- The Compensation Committee had not approved a non-employee director compensation plan.
- September 2025 restricted stock units vest in full on the third anniversary, subject to continuous service.
Other Citius Oncology proxy statements
- 2025 proxy statement
Leonard Mazur paid $2.2M (+233% on the year).
Filed Sep 26, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.